PURPOSE: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is expressed on 95% of colorectal cancers. A previous study has shown excellent tumor-targeting of iodine-131 labeled huA33 (131I-huA33). Therefore, we did a phase I dose escalation trial of 131I-huA33 radioimmunotherapy. EXPERIMENTAL DESIGNS: Fifteen patients with pretreated metastatic colorectal carcinoma each received two i.v. doses of 131I-huA33. The first was an outpatient trace-labeled "scout" dose for biodistribution assessment, followed by a second "therapy" dose. Three patients were treated at 20, 30, and 40 mCi/m2 dose levels, and six patients at 50 mCi/m2 to define the maximum tolerated dose. RESULTS: Hematologic toxicity was 131I dose-dependent, with one episode of grade 4 neutropenia and two episodes of grade 3 thrombocytopenia observed at 50 mCi/m2. The maximum tolerated dose was determined to be 40 mCi/m2. There were no acute infusion-related adverse events, and gastrointestinal toxicity was not observed despite uptake of 131I-huA33 in bowel. Seven patients developed pruritus or rash, which was not related to 131I dose. There was excellent tumor-targeting of 131I-huA33 shown in all patients. The serum T1/2beta of 131I-huA33 was (mean +/- SD) 135.2 +/- 46.9 hours. The mean absorbed tumor dose was 6.49 +/- 2.47 Gy/GBq. Four patients developed human anti-human antibodies. At restaging, 4 patients had stable disease, whereas 11 patients had progressive disease. CONCLUSION: Radioimmunotherapy using 131I-huA33 shows promise in targeting colorectal tumors, and is deliverable at a maximum tolerated dose of 40 mCi/m2. Further studies of 131I-huA33 in combination with chemotherapy are planned.
PURPOSE: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is expressed on 95% of colorectal cancers. A previous study has shown excellent tumor-targeting of iodine-131 labeled huA33 (131I-huA33). Therefore, we did a phase I dose escalation trial of 131I-huA33 radioimmunotherapy. EXPERIMENTAL DESIGNS: Fifteen patients with pretreated metastatic colorectal carcinoma each received two i.v. doses of 131I-huA33. The first was an outpatient trace-labeled "scout" dose for biodistribution assessment, followed by a second "therapy" dose. Three patients were treated at 20, 30, and 40 mCi/m2 dose levels, and six patients at 50 mCi/m2 to define the maximum tolerated dose. RESULTS: Hematologic toxicity was 131I dose-dependent, with one episode of grade 4 neutropenia and two episodes of grade 3 thrombocytopenia observed at 50 mCi/m2. The maximum tolerated dose was determined to be 40 mCi/m2. There were no acute infusion-related adverse events, and gastrointestinal toxicity was not observed despite uptake of 131I-huA33 in bowel. Seven patients developed pruritus or rash, which was not related to 131I dose. There was excellent tumor-targeting of 131I-huA33 shown in all patients. The serum T1/2beta of 131I-huA33 was (mean +/- SD) 135.2 +/- 46.9 hours. The mean absorbed tumor dose was 6.49 +/- 2.47 Gy/GBq. Four patients developed human anti-human antibodies. At restaging, 4 patients had stable disease, whereas 11 patients had progressive disease. CONCLUSION: Radioimmunotherapy using 131I-huA33 shows promise in targeting colorectal tumors, and is deliverable at a maximum tolerated dose of 40 mCi/m2. Further studies of 131I-huA33 in combination with chemotherapy are planned.
Authors: Joseph A O'Donoghue; Peter M Smith-Jones; John L Humm; Shutian Ruan; Daniel A Pryma; Achim A Jungbluth; Chaitanya R Divgi; Jorge A Carrasquillo; Neeta Pandit-Taskar; Yuman Fong; Vivian E Strong; Nancy E Kemeny; Lloyd J Old; Steven M Larson Journal: J Nucl Med Date: 2011-11-08 Impact factor: 10.057
Authors: Sarah M Cheal; Edward K Fung; Mitesh Patel; Hong Xu; Hong-Fen Guo; Pat B Zanzonico; Sebastien Monette; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson Journal: J Nucl Med Date: 2017-07-13 Impact factor: 10.057
Authors: Jorge A Carrasquillo; Neeta Pandit-Taskar; Joseph A O'Donoghue; John L Humm; Pat Zanzonico; Peter M Smith-Jones; Chaitanya R Divgi; Daniel A Pryma; Shutian Ruan; Nancy E Kemeny; Yuman Fong; Douglas Wong; Jaspreet S Jaggi; David A Scheinberg; Mithat Gonen; Katherine S Panageas; Gerd Ritter; Achim A Jungbluth; Lloyd J Old; Steven M Larson Journal: J Nucl Med Date: 2011-07-15 Impact factor: 10.057
Authors: Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos Journal: Nanomedicine (Lond) Date: 2016-08-16 Impact factor: 5.307
Authors: Stephen Shibata; Andrew Raubitschek; Lucille Leong; Marianna Koczywas; Lawrence Williams; Jiping Zhan; Jeffrey Y C Wong Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Lawrence T Dauer; Daniel C Boylan; Matthew J Williamson; Jean St Germain; Steven M Larson Journal: Health Phys Date: 2009-05 Impact factor: 1.316
Authors: Margaret E Ackerman; Cecile Chalouni; Michael M Schmidt; Vivek V Raman; Gerd Ritter; Lloyd J Old; Ira Mellman; K Dane Wittrup Journal: Cancer Immunol Immunother Date: 2008-07 Impact factor: 6.968
Authors: Marcus P Kelly; Sze Ting Lee; F-T Lee; Fiona E Smyth; Ian D Davis; Martin W Brechbiel; Andrew M Scott Journal: Prostate Date: 2009-01-01 Impact factor: 4.104